Gilteritinib as Maintenance Therapy Shows Benefit in Subgroups of FLT3-ITD
09 Jun 2023 //
PR NEWSWIRE
Astellas Xospata comes up short again in bid to expand leukemia use
10 Mar 2023 //
FIERCE PHARMA
Astellas and BMT CTN Announce Results from PIII MORPHO Trial of Gilteritinib
09 Mar 2023 //
PR NEWSWIRE
Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib
22 Aug 2022 //
GLOBENEWSWIRE
Gilteritinib clinical activity in r/r FLT3 mutated AML
12 Jan 2022 //
ONLINELIBRARY
Astellas finds the silver lining in failed trial for Xospata
15 Dec 2021 //
FIERCEPHARMA
Astellas` XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE
29 Mar 2021 //
PRNEWSWIRE
Astellas` XOSPATA® (gilteritinib) Receives Conditional Approval by China`s
03 Feb 2021 //
PRNEWSWIRE
Astellas to Present New Data on Gilteritinib in FLT3 Mutation-+VE Acute Myeloid
16 Nov 2020 //
PRNEWSWIRE
NICE publishes guidance on Astellas` Xospata
17 Aug 2020 //
PHARMATIMES
Astellas’ Q1 Sales Falter 8% on Deal Terminations, COVID-19
05 Aug 2020 //
JIHO
NICE recommends Astellas’ Xospata for NHS use
18 Jul 2020 //
PMLIVE
Gilteritinib becomes 1st NICE-approved oral therapy for relapsed refractory AML
15 Jul 2020 //
PHARMAFILLE
Astellas Announces Acceptance of XOSPATA® (gilteritinib) for Regulatory Review
10 Apr 2020 //
PRESS RELEASE
Merck`s Keytruda faces NICE pushback as Ibrance, Lynparza grab green lights
16 Jan 2020 //
FIERCE PHARMA
Health Canada Approves Astellas` XOSPATA®
14 Jan 2020 //
FIANACE YAHOO
Astellas Presents New Data on XOSPATA® (gilteritinib)
03 Dec 2019 //
PRESS RELEASE
New England Journal of Medicine Publishes Results from Astellas` Ph3 XOSPATA®
01 Nov 2019 //
PR NEWSWIRE
New England Journal of Medicine Publishes Results from Astellas` Ph3 XOSPATA®
31 Oct 2019 //
PR NEWSWIRE
European Commission Approves Astellas` XOSPATA™
30 Oct 2019 //
PRNEWSWIRE
Xospata bags European Commission approval
26 Oct 2019 //
PHARMATIMES
Astellas stays ahead of its FLT3 rivals with EU nod for Xospata
26 Oct 2019 //
PMLIVE
Astellas’ Xospata scores positive CHMP recommendation
24 Sep 2019 //
PMLIVE
Xospata leads latest CHMP recommendations
21 Sep 2019 //
PHARMATIMES
EMA`s CHMP Recommends Three New Medicines
20 Sep 2019 //
RAPS
Astellas` AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
20 Sep 2019 //
ENDPTS
Celgene`s AML drug clears late-stage test
16 Sep 2019 //
ENDPTS
FDA nixes Daiichi’s quizartinib after Japanese regulators wave it through
22 Jun 2019 //
FIERCE BIOTECH
Astellas Pharma receives US FDA approval to update labelling for Xospata
01 Jun 2019 //
PHARMABIZ
Daiichi`s Xospata rival pushed back by FDA
05 Apr 2019 //
FIERCE BIOTECH
Pha 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib)
02 Apr 2019 //
PRESS RELEASE
Penn presents positive results for targeted leukaemia drug
01 Apr 2019 //
PHARMACEUTICAL TECHNOLOGY
Astellas pads Xospata lead with AML survival data
01 Apr 2019 //
FIERCE PHARMA
EMA accepts marketing authorisation applications for Idefirix and Xospata
04 Mar 2019 //
PHARMA TIMES
FDA stamps fast OK on Astellas’ pioneering FLT3 AML drug gilteritinib
29 Nov 2018 //
ENDPTS
Invivoscribe® Receives Approval in Japan for CDx FLT3 Mutation Assay
26 Sep 2018 //
GLOBENEWSWIRE
Priority review for Astellas’ AML drug
31 May 2018 //
PHARMA TIMES
Astellas Submits NDA for Approval of Gilteritinib for the Treatment of FLT3mut
23 Apr 2018 //
PR NEWSWIRE